Avadel Pharmaceuticals PLC
NASDAQ:AVDL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Avadel Pharmaceuticals PLC
Retained Earnings
Avadel Pharmaceuticals PLC
Retained Earnings Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Retained Earnings | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
|
Retained Earnings
-$789.6m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-10%
|
|
|
Perrigo Company PLC
NYSE:PRGO
|
Retained Earnings
-$3.7B
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
|
|
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
|
Retained Earnings
$646.6m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
8%
|
|
|
G
|
GH Research PLC
NASDAQ:GHRS
|
Retained Earnings
-$141.1m
|
CAGR 3-Years
-68%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Cosmo Pharmaceuticals NV
SIX:COPN
|
Retained Earnings
€374.6m
|
CAGR 3-Years
3%
|
CAGR 5-Years
2%
|
CAGR 10-Years
-1%
|
|
|
Ovoca Bio PLC
LSE:OVB
|
Retained Earnings
-€14.5m
|
CAGR 3-Years
-151%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Avadel Pharmaceuticals PLC
Glance View
Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. The company is headquartered in Dublin, Dublin and currently employs 66 full-time employees. The Company’s lead product candidate, FT218, is an investigational once-nightly formulation of sodium oxybate for the treatment of excessive daytime sleepiness (EDS), and cataplexy in narcolepsy patients. Its Micropump allows for the development of modified and/or controlled release solid, oral dosage formulations of drugs. Its LiquiTime technology allows for development of modified/controlled release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its Medusa technology allows for the development of extended-/modified-release injectable dosage formulations of drugs.
See Also
What is Avadel Pharmaceuticals PLC's Retained Earnings?
Retained Earnings
-789.6m
USD
Based on the financial report for Sep 30, 2025, Avadel Pharmaceuticals PLC's Retained Earnings amounts to -789.6m USD.
What is Avadel Pharmaceuticals PLC's Retained Earnings growth rate?
Retained Earnings CAGR 10Y
-10%
Over the last year, the Retained Earnings growth was 0%. The average annual Retained Earnings growth rates for Avadel Pharmaceuticals PLC have been -12% over the past three years , -16% over the past five years , and -10% over the past ten years .
